|
1
|
Jung KW, Park S, Kong HJ, et al: Cancer
statistics in Korea: incidence, mortality, survival, and prevalence
in 2008. Cancer Res Treat. 43:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rastogi P, Anderson SJ, Bear HD, et al:
Preoperative chemotherapy: updates of National Surgical Adjuvant
Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol.
26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mauri D, Pavlidis N and Ioannidis JP:
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a
meta-analysis. J Natl Cancer Inst. 97:188–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Darb-Esfahani S, Loibl S, Muller BM, et
al: Identification of biology-based breast cancer types with
distinct predictive and prognostic features: role of steroid
hormone and HER2 receptor expression in patients treated with
neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer
Res. 11:R692009. View
Article : Google Scholar
|
|
5
|
Chang HR, Glaspy J, Allison MA, et al:
Differential response of triple-negative breast cancer to a
docetaxel and carboplatin-based neoadjuvant treatment. Cancer.
116:4227–4237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Christensen BC, Kelsey KT, Zheng S, et al:
Breast cancer DNA methylation profiles are associated with tumor
size and alcohol and folate intake. PLoS Genet. 6:e10010432010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan PS, Shi H, Rahmatpanah F, et al:
Differential distribution of DNA methylation within the RASSF1A CpG
island in breast cancer. Cancer Res. 63:6178–6186. 2003.PubMed/NCBI
|
|
8
|
Yeo W, Wong WL, Wong N, Law BK, Tse GM and
Zhong S: High frequency of promoter hypermethylation of RASSF1A in
tumorous and non-tumourous tissue of breast cancer. Pathology.
37:125–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Honorio S, Agathanggelou A, Schuermann M,
et al: Detection of RASSF1A aberrant promoter hypermethylation in
sputum from chronic smokers and ductal carcinoma in situ from
breast cancer patients. Oncogene. 22:147–150. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shukla S, Mirza S, Sharma G, Parshad R,
Gupta SD and Ralhan R: Detection of RASSF1A and RARbeta
hypermethylation in serum DNA from breast cancer patients.
Epigenetics. 1:88–93. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yazici H, Terry MB, Cho YH, et al:
Aberrant methylation of RASSF1A in plasma DNA before breast cancer
diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol
Biomarkers Prev. 18:2723–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kioulafa M, Kaklamanis L, Mavroudis D,
Georgoulias V and Lianidou ES: Prognostic significance of RASSF1A
promoter methylation in operable breast cancer. Clin Biochem.
42:970–975. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karray-Chouayekh S, Trifa F, Khabir A, et
al: Aberrant methylation of RASSF1A is associated with poor
survival in Tunisian breast cancer patients. J Cancer Res Clin
Oncol. 136:203–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martins AT, Monteiro P, Ramalho-Carvalho
J, et al: High RASSF1A promoter methylation levels are predictive
of poor prognosis in fine-needle aspirate washings of breast cancer
lesions. Breast Cancer Res Treat. 129:1–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim DH, Kim JS, Ji YI, et al:
Hypermethylation of RASSF1A promoter is associated with the age at
starting smoking and a poor prognosis in primary non-small cell
lung cancer. Cancer Res. 63:3743–3746. 2003.PubMed/NCBI
|
|
16
|
Wang J, Lee JJ, Wang L, et al: Value of
p16INK4a and RASSF1A promoter hypermethylation in prognosis of
patients with resectable non-small cell lung cancer. Clin Cancer
Res. 10:6119–6125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seidel C, Bartel F, Rastetter M, et al:
Alterations of cancer-related genes in soft tissue sarcomas:
hypermethylation of RASSF1A is frequently detected in
leiomyosarcoma and associated with poor prognosis in sarcoma. Int J
Cancer. 114:442–447. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fischer JR, Ohnmacht U, Rieger N, et al:
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor
prognosis of patients with malignant mesothelioma. Lung Cancer.
54:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahmed-Choudhury J, Agathanggelou A, Fenton
SL, et al: Transcriptional regulation of cyclin A2 by RASSF1A
through the enhanced binding of p120E4F to the cyclin A2 promoter.
Cancer Res. 65:2690–2697. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song MS, Song SJ, Ayad NG, et al: The
tumour suppressor RASSF1A regulates mitosis by inhibiting the
APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L, Tommasi S, Lee DH, Dammann R and
Pfeifer GP: Control of microtubule stability by the RASSF1A tumor
suppressor. Oncogene. 22:8125–8136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Whang YM, Park KH, Jung HY, Jo UH and Kim
YH: Microtubule-damaging agents enhance RASSF1A-induced cell death
in lung cancer cell lines. Cancer. 115:1253–1266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reu FJ, Bae SI, Cherkassky L, et al:
Overcoming resistance to interferon-induced apoptosis of renal
carcinoma and melanoma cells by DNA demethylation. J Clin Oncol.
24:3771–3779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reu FJ, Leaman DW, Maitra RR, et al:
Expression of RASSF1A, an epigenetically silenced tumor suppressor,
overcomes resistance to apoptosis induction by interferons. Cancer
Res. 66:2785–2793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
27
|
Pallares J, Velasco A, Eritja N, et al:
Promoter hypermethylation and reduced expression of RASSF1A are
frequent molecular alterations of endometrial carcinoma. Mod
Pathol. 21:691–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ateeq B, Unterberger A, Szyf M and Rabbani
SA: Pharmacological inhibition of DNA methylation induces
proinvasive and prometastatic genes in vitro and in vivo.
Neoplasia. 10:266–278. 2008.PubMed/NCBI
|
|
29
|
Liu Z, Wu J, Xie Z, et al: Quantification
of regional DNA methylation by liquid chromatography/tandem mass
spectrometry. Anal Biochem. 391:106–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
|
|
31
|
Caudle AS, Gonzalez-Angulo AM, Hunt KK, et
al: Predictors of tumor progression during neoadjuvant chemotherapy
in breast cancer. J Clin Oncol. 28:1821–1828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Coon JS, Marcus E, Gupta-Burt S, et al:
Amplification and overexpression of topoisomerase IIalpha predict
response to anthracycline-based therapy in locally advanced breast
cancer. Clin Cancer Res. 8:1061–1067. 2002.PubMed/NCBI
|
|
33
|
Gascoigne KE and Taylor SS: How do
anti-mitotic drugs kill cancer cells? J Cell Sci. 122:2579–2585.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gascoigne KE and Taylor SS: Cancer cells
display profound intra- and interline variation following prolonged
exposure to antimitotic drugs. Cancer Cell. 14:111–122. 2008.
View Article : Google Scholar
|
|
35
|
Whang YM, Kim YH, Kim JS and Yoo YD:
RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell
cycle progression. Cancer Res. 65:3682–3690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Allan LA and Clarke PR: Phosphorylation of
caspase-9 by CDK1/cyclin B1 protects mitotic cells against
apoptosis. Mol Cell. 26:301–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
